- Report
- November 2024
- 120 Pages
Global
From €5228EUR$5,950USD£4,510GBP
- Report
- November 2024
- 150 Pages
Global
From €5228EUR$5,950USD£4,510GBP
- Report
- November 2024
- 120 Pages
Global
From €5228EUR$5,950USD£4,510GBP
- Report
- October 2024
- 140 Pages
Global
From €5228EUR$5,950USD£4,510GBP
- Report
- October 2024
- 120 Pages
Global
From €5228EUR$5,950USD£4,510GBP
- Report
- October 2024
- 150 Pages
Global
From €5228EUR$5,950USD£4,510GBP
- Report
- June 2025
- 200 Pages
Global
From €2188EUR$2,490USD£1,887GBP
- Report
- November 2024
- 100 Pages
Global
From €2188EUR$2,490USD£1,887GBP
- Report
- April 2025
- 200 Pages
Global
From €2188EUR$2,490USD£1,887GBP
- Report
- April 2025
- 175 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- April 2025
- 200 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- April 2025
- 200 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- April 2025
- 200 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- April 2025
- 200 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- March 2025
- 200 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- March 2025
- 200 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- March 2025
- 175 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- March 2025
- 175 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- March 2025
- 250 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- February 2025
- 200 Pages
Global
From €3945EUR$4,490USD£3,403GBP

The biologic market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs. Biologic drugs are made from living organisms, such as proteins, nucleic acids, and cells, and are used to treat a variety of diseases. These drugs are typically more complex and expensive to produce than traditional small-molecule drugs. The biologic market is highly competitive, with many companies vying for market share.
The biologic market is divided into two main segments: therapeutic biologics and biosimilars. Therapeutic biologics are drugs that are developed to treat a specific disease or condition, while biosimilars are drugs that are similar to existing biologic drugs but are not identical.
Some of the major players in the biologic market include Amgen, Biogen, Celgene, Gilead Sciences, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. These companies are involved in the development, production, and marketing of biologic drugs. Show Less Read more